Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Socher cites Perilbio, which uses tiny organoids to test drug interactions with human immune and neural systems. He says these tests are more predictive than mouse studies, and Perilbio received FDA approval to skip animal trials for immune-therapy toxicity testing, saving animal lives and speeding drugs to market. Organoids are smaller than a bee.

Related Insights

The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

Non-human primate models are poor predictors of human immunogenicity. The industry has shifted to human-relevant ex vivo assays using whole blood or PBMCs. These tests can assess risks like complement activation upfront, enabling proactive protein engineering to improve a drug's safety profile.

Yale spin-out Bexorg uses donated, post-mortem human brains kept molecularly active to test CNS drugs. This novel platform's key advantage is its ability to directly measure pharmacokinetics and blood-brain barrier penetration in a complex human organ, addressing a primary reason for clinical trial failure that animal and cell models cannot adequately predict.

The push away from animal models is a technical necessity, not just an ethical one. Advanced therapeutics like T-cell engagers and multispecific antibodies depend on human-specific biological pathways. These mechanisms are not accurately reproduced in animal models, rendering them ineffective for testing these new drug classes.

With support from the FDA and NIH, the industry is moving to standardize organoid systems. This shift transforms them from niche research tools into reliable, quality-controlled preclinical models that can be used for personalized medicine and to generate more predictable drug discovery data.

Only 5% of investigational cancer drugs reach the market due to the gap between lab models and human biology. Dr. Saav Solanki highlights organoids, which use real patient tissue, as a key translational model to improve the predictive accuracy of preclinical research and increase the low success rate.

Medera's platform engineers healthy and diseased human heart chambers to test drug toxicity and efficacy. This directly addresses cardiac safety, a primary reason for drug failure across all therapeutic areas, not just heart-related treatments. This human-based data was crucial for securing their FDA IND clearance.

Contrary to the common narrative of regulators slowing innovation, the FDA has enacted multiple "modernization acts" to encourage the adoption of technologies like lab-grown human tissues. This is especially crucial for modern biologic drugs that are human-specific and don't translate well from animal models.

The NIH will no longer award funding to new grant proposals that rely exclusively on animal models. This policy forces a shift towards New Approach Methodologies (NAMs), such as organoids and organ-on-chips, serving as a major catalyst for innovation and adoption in the preclinical testing space.

The FDA is eliminating mandatory animal testing because it's often misleading—90% of drugs passing animal studies fail in humans. The agency is embracing modern alternatives like computational modeling and organ-on-a-chip technology to get faster, more accurate safety data.